Roche, Obesity
(RTTNews) - Swiss drug major Roche Group (RHHBY), at its Pharma Day 2024, said it expects sales momentum to continue into 2025, with strong growth by both divisions of Pharma and Diagnostics. The ...
Roche is planning to launch 13 medicines by the end of the decade and cut research costs for new drugs by a fifth, according to a strategy update on Monday.
Roche’s current pharmaceutical portfolio will deliver growth through at least 2027, the company said. Schinecker has already ...
Basel, Switzerland and Vacaville, US, 1 October 2024 – Lonza, one of the world’s largest healthcare development and manufacturing organizations, today announced it has completed its acquisition of the ...
The Temperature-Activated Generation of Signal (TAGS) technology was developed by Roche for its high-throughput PCR-based instruments.
Typically, when clinicians assess a certain group of targets first ... diagnostic results per well - all out of a single test kit. Roche’s new TAGS technology overcomes the technical limitations ...
Chinese Vice Premier He Lifeng met with Severin Schwan chairman of the Board of Directors of Roche Group in Beijing on Friday evening He also a me ...
Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus ...
The the Swiss drugmaker will face off in the obesity area with leaders Novo Nordisk A/S and Indianapolis-based Eli Lilly and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback